GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
last added cars
2022-10-21| Licensing

Kite to Use Refuge’s Gene Expression Platform for New CAR-T Therapies

by Reed Slater
Share To

CAR-T Cell therapy superstar Kite entered a global licensing agreement with Refuge Biotechnologies Inc. to leverage Refuge’s proprietary gene expression platform to develop new CAR-T therapies targeting blood cancer. Kite, a Gilead company, will take the reins, covering all research, development, manufacturing, and commercialization costs.

Building on a Successful CAR-T Platform

Kite developed and commercialized two of the five CAR-T cell therapies currently on the market, making them one of the most influential companies in the space. The agreement with Refuge could bring another layer of complexity and value to Kite’s portfolio. 

Refuge’s gene expression platform leverages synthetic biology and uses an expression modulation strategy to repress or activate the transcription of gene targets. According to Kite’s press release, the modular platform shows the potential to improve the safety and efficacy rates of CAR-T therapies. 

Francesco Marincola, MD, Global Head of Cell Therapy Research at Kite, said, “Through this exclusive license agreement with Refuge’s platform, coupled with our unique in-house research capabilities, we aim to create a new generation of CAR T-cell products to induce long-term remissions for more patients.”

Related Article: Synthetic Biology: A Rising Interdisciplinary Field that Revolutionizes the Biomedical Industry

Piecing Together the Terms of the Deal

So far, Kite’s approved CAR-T cell therapies only target blood cancer, and the agreement with Refuge would keep them on that path. As part of the deal, Kite would receive the exclusive license to Refuge’s intellectual property portfolio for use in blood cancers. Refuge will retain the rights for any programs related to solid tumor indications. 

Keeping potential solid tumor indications is right up Refuge’s alley, though, because it has two CAR-T candidates in its pipeline seemingly bound for the clinic. According to Refuge’s pipeline, two CAR-T therapies targeting HER2 are in late-preclinical development. 

Chief Business Officer at Refuge, Jing Zhao, said, “As a leader in the advancement of cell therapy from research to life-changing therapeutics, Kite is an ideal partner for Refuge as we seek to further evaluate the promise of Refuge’s proprietary platform. We look forward to collaborating closely with Kite in this area, while continuing to advance our internal therapeutic research and programs focused on solid tumors.”

Kite will pay Refuge an undisclosed amount of cash upfront as part of the deal. Other benefits may include future performance-based regulatory milestone payments, which are also undisclosed. 

The license agreement between Kite and Refuge is exciting for CAR-T cell’s future. Kite, which has valuable experience in blood cancer-targeting CAR-T cell therapies, could use Refuge’s gene expression platform to create a new generation of CAR-T cell therapies that are safer and more effective than previous iterations.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease
2025-02-07
FDA Investigates Reports of Blood Cancer Cases Linked to Gene Therapy
2024-12-02
M&A
Gilead Sciences Acquires CymaBay for $4.3 billion, Heralding a New Era in PBC Treatment
2024-02-15
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top